2 recruiting, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow XIANG YANQUN: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial TPC combined with Apatinib and Camrelizumab, GP Combined With Camrelizumab - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | XIANG YANQUN | 164 | 2024-05-30 | 2024-07-16 |
| Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. GP combined with Tislelizumab, TPC combined with Tislelizumab - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | XIANG YANQUN | 90 | 2024-05-15 | 2024-07-16 |
| Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma Capecitabine/Placebo combined with toripalimab - Nasopharyngeal Carcinoma, Maintenance Therapy | Phase 3 | Active not recruiting | XIANG YANQUN | 166 | 2023-04-28 | 2024-12-30 |
Capecitabine (1) · apatinib (1) · camrelizumab (1) · tislelizumab (1) · toripalimab (1)
China (3)
Yanqun Xiang (1)